Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations

Padraig E. O'Suilleabhain, Victor Sung, Carlos Hernandez, Laura Lacritz, Richard B. Dewey, Teodoro Bottiglieri, Ramon Diaz-Arrastia

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Background: An elevated plasma homocysteine (Hcy) level has been prospectively associated with an increased risk of vascular and degenerative dementias. An Hcy elevation is prevalent in patients with Parkinson disease (PD) in part because levodopa metabolism produces Hcy. The clinical relevance of an elevated Hcy level in patients with PD is unknown. Objective: To determine if hyperhomocysteinemia in patients with PD is associated with depression or with cognitive or physical impairments. Design: Ninety-seven people with a mean (SD) PD duration of 3.6 (1.6) years completed the Beck Depression Inventory, a battery of 11 cognitive tests, and the motor and function components of the Unified Parkinson's Disease Rating Scale. Normalized scores for the affective, cognitive, and physical measures were compared between those with a normal Hcy level (n= 66) and those with hyperhomocysteinemia (n=31) (Hcy level, >1.89 mg/L [>14 μmol/L]), controlling for age, sex, disease duration, and treatment. Results: Subjects with an elevated Hcy level were slightly older (68 vs 62 years), but had similar plasma concentrations of vitamin B12 and folate. Hyperhomocysteinemic patients were more depressed (P=.02) and had worse cognition (P<.01), but the physical measure did not differ. Conclusions: Patients with PD and hyperhomocysteinemia are more likely to be depressed and to perform worse on neuropsychometric tasks compared with normohomocysteinemic patients. Further research is warranted to see if hyperhomocysteinemia is a reversible risk factor for neuropsychiatric burden in patients with PD.

Original languageEnglish (US)
Pages (from-to)865-868
Number of pages4
JournalArchives of Neurology
Volume61
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Homocysteine
Parkinson Disease
Hyperhomocysteinemia
Depression
Vascular Dementia
Levodopa
Vitamin B 12
Affective
Plasma
Parkinson's Disease
Folic Acid
Cognition
Equipment and Supplies
Research
Physical

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Elevated plasma homocysteine level in patients with Parkinson disease : Motor, affective, and cognitive associations. / O'Suilleabhain, Padraig E.; Sung, Victor; Hernandez, Carlos; Lacritz, Laura; Dewey, Richard B.; Bottiglieri, Teodoro; Diaz-Arrastia, Ramon.

In: Archives of Neurology, Vol. 61, No. 6, 06.2004, p. 865-868.

Research output: Contribution to journalArticle

@article{cc48b1b2ad5c45bca24294a424e76bfb,
title = "Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations",
abstract = "Background: An elevated plasma homocysteine (Hcy) level has been prospectively associated with an increased risk of vascular and degenerative dementias. An Hcy elevation is prevalent in patients with Parkinson disease (PD) in part because levodopa metabolism produces Hcy. The clinical relevance of an elevated Hcy level in patients with PD is unknown. Objective: To determine if hyperhomocysteinemia in patients with PD is associated with depression or with cognitive or physical impairments. Design: Ninety-seven people with a mean (SD) PD duration of 3.6 (1.6) years completed the Beck Depression Inventory, a battery of 11 cognitive tests, and the motor and function components of the Unified Parkinson's Disease Rating Scale. Normalized scores for the affective, cognitive, and physical measures were compared between those with a normal Hcy level (n= 66) and those with hyperhomocysteinemia (n=31) (Hcy level, >1.89 mg/L [>14 μmol/L]), controlling for age, sex, disease duration, and treatment. Results: Subjects with an elevated Hcy level were slightly older (68 vs 62 years), but had similar plasma concentrations of vitamin B12 and folate. Hyperhomocysteinemic patients were more depressed (P=.02) and had worse cognition (P<.01), but the physical measure did not differ. Conclusions: Patients with PD and hyperhomocysteinemia are more likely to be depressed and to perform worse on neuropsychometric tasks compared with normohomocysteinemic patients. Further research is warranted to see if hyperhomocysteinemia is a reversible risk factor for neuropsychiatric burden in patients with PD.",
author = "O'Suilleabhain, {Padraig E.} and Victor Sung and Carlos Hernandez and Laura Lacritz and Dewey, {Richard B.} and Teodoro Bottiglieri and Ramon Diaz-Arrastia",
year = "2004",
month = "6",
doi = "10.1001/archneur.61.6.865",
language = "English (US)",
volume = "61",
pages = "865--868",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Elevated plasma homocysteine level in patients with Parkinson disease

T2 - Motor, affective, and cognitive associations

AU - O'Suilleabhain, Padraig E.

AU - Sung, Victor

AU - Hernandez, Carlos

AU - Lacritz, Laura

AU - Dewey, Richard B.

AU - Bottiglieri, Teodoro

AU - Diaz-Arrastia, Ramon

PY - 2004/6

Y1 - 2004/6

N2 - Background: An elevated plasma homocysteine (Hcy) level has been prospectively associated with an increased risk of vascular and degenerative dementias. An Hcy elevation is prevalent in patients with Parkinson disease (PD) in part because levodopa metabolism produces Hcy. The clinical relevance of an elevated Hcy level in patients with PD is unknown. Objective: To determine if hyperhomocysteinemia in patients with PD is associated with depression or with cognitive or physical impairments. Design: Ninety-seven people with a mean (SD) PD duration of 3.6 (1.6) years completed the Beck Depression Inventory, a battery of 11 cognitive tests, and the motor and function components of the Unified Parkinson's Disease Rating Scale. Normalized scores for the affective, cognitive, and physical measures were compared between those with a normal Hcy level (n= 66) and those with hyperhomocysteinemia (n=31) (Hcy level, >1.89 mg/L [>14 μmol/L]), controlling for age, sex, disease duration, and treatment. Results: Subjects with an elevated Hcy level were slightly older (68 vs 62 years), but had similar plasma concentrations of vitamin B12 and folate. Hyperhomocysteinemic patients were more depressed (P=.02) and had worse cognition (P<.01), but the physical measure did not differ. Conclusions: Patients with PD and hyperhomocysteinemia are more likely to be depressed and to perform worse on neuropsychometric tasks compared with normohomocysteinemic patients. Further research is warranted to see if hyperhomocysteinemia is a reversible risk factor for neuropsychiatric burden in patients with PD.

AB - Background: An elevated plasma homocysteine (Hcy) level has been prospectively associated with an increased risk of vascular and degenerative dementias. An Hcy elevation is prevalent in patients with Parkinson disease (PD) in part because levodopa metabolism produces Hcy. The clinical relevance of an elevated Hcy level in patients with PD is unknown. Objective: To determine if hyperhomocysteinemia in patients with PD is associated with depression or with cognitive or physical impairments. Design: Ninety-seven people with a mean (SD) PD duration of 3.6 (1.6) years completed the Beck Depression Inventory, a battery of 11 cognitive tests, and the motor and function components of the Unified Parkinson's Disease Rating Scale. Normalized scores for the affective, cognitive, and physical measures were compared between those with a normal Hcy level (n= 66) and those with hyperhomocysteinemia (n=31) (Hcy level, >1.89 mg/L [>14 μmol/L]), controlling for age, sex, disease duration, and treatment. Results: Subjects with an elevated Hcy level were slightly older (68 vs 62 years), but had similar plasma concentrations of vitamin B12 and folate. Hyperhomocysteinemic patients were more depressed (P=.02) and had worse cognition (P<.01), but the physical measure did not differ. Conclusions: Patients with PD and hyperhomocysteinemia are more likely to be depressed and to perform worse on neuropsychometric tasks compared with normohomocysteinemic patients. Further research is warranted to see if hyperhomocysteinemia is a reversible risk factor for neuropsychiatric burden in patients with PD.

UR - http://www.scopus.com/inward/record.url?scp=2942525889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942525889&partnerID=8YFLogxK

U2 - 10.1001/archneur.61.6.865

DO - 10.1001/archneur.61.6.865

M3 - Article

C2 - 15210523

AN - SCOPUS:2942525889

VL - 61

SP - 865

EP - 868

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 6

ER -